share_log

6,894 Shares in ZimVie Inc. (NASDAQ:ZIMV) Purchased by Oregon Public Employees Retirement Fund

6,894 Shares in ZimVie Inc. (NASDAQ:ZIMV) Purchased by Oregon Public Employees Retirement Fund

俄勒冈州公共雇员退休基金购买了ZimVie Inc.(纳斯达克股票代码:ZIMV)的6,894股股票
Defense World ·  2023/01/29 06:32

Oregon Public Employees Retirement Fund bought a new stake in ZimVie Inc. (NASDAQ:ZIMV – Get Rating) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,894 shares of the company's stock, valued at approximately $68,000.

俄勒冈州公共雇员退休基金根据向美国证券交易委员会提交的最新13F文件,在第三季度购买了ZimVie Inc.(纳斯达克股票代码:ZIMV — Get Rating)的新股份。该基金购买了该公司6,894股股票,价值约68,000美元。

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Monarch Capital Management Inc. acquired a new position in ZimVie in the third quarter valued at approximately $227,000. Hellman Jordan Management Co. Inc. MA acquired a new position in ZimVie in the second quarter valued at approximately $724,000. Douglas Lane & Associates LLC acquired a new position in ZimVie in the third quarter valued at approximately $192,000. Raymond James & Associates acquired a new position in ZimVie in the third quarter valued at approximately $110,000. Finally, Comerica Bank acquired a new position in ZimVie in the third quarter valued at approximately $110,000. 74.29% of the stock is currently owned by institutional investors and hedge funds.

其他对冲基金和其他机构投资者最近也买入和卖出了该公司的股票。Monarch Capital Management Inc.在第三季度收购了ZimVie的新职位,价值约22.7万美元。赫尔曼·乔丹管理公司Inc. MA在第二季度收购了ZimVie的新职位,价值约72.4万美元。Douglas Lane & Associates LLC在第三季度收购了ZimVie的新职位,价值约19.2万美元。Raymond James & Associates在第三季度收购了ZimVie的新职位,价值约11万美元。最后,Comerica Bank在第三季度收购了ZimVie的新头寸,价值约11万美元。该股票的74.29%目前由机构投资者和对冲基金持有。

Get
获取
ZimVie
ZimVi
alerts:
警报:

Analyst Upgrades and Downgrades

分析师升级和降级

Separately, Barclays assumed coverage on ZimVie in a research note on Wednesday, December 21st. They issued an "underweight" rating and a $9.00 target price for the company.

另外,巴克莱银行在12月21日星期三的一份研究报告中假设对ZimVie进行了报道。他们发布了 “减持” 评级和9.00美元的公司目标价格。

ZimVie Price Performance

ZimVie 价格表现

Shares of NASDAQ ZIMV opened at $9.09 on Friday. The company has a current ratio of 2.51, a quick ratio of 1.48 and a debt-to-equity ratio of 0.76. The stock has a 50 day simple moving average of $8.95 and a 200-day simple moving average of $11.74. ZimVie Inc. has a 12-month low of $6.67 and a 12-month high of $50.40.
纳斯达克ZIMV的股价周五开盘价为9.09美元。该公司的流动比率为2.51,速动比率为1.48,债务与权益比率为0.76。该股的50天简单移动平均线为8.95美元,200天简单移动平均线为11.74美元。ZimVie Inc.创下12个月低点6.67美元,12个月高点为50.40美元。

ZimVie (NASDAQ:ZIMV – Get Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.22. The business had revenue of $214.58 million during the quarter, compared to the consensus estimate of $214.83 million. ZimVie had a negative return on equity of 2.75% and a negative net margin of 9.96%. On average, equities analysts expect that ZimVie Inc. will post 1.95 earnings per share for the current year.

ZimVie(纳斯达克股票代码:ZIMV — Get Rating)上次发布季度收益数据是在11月9日星期三。该公司公布本季度每股收益(EPS)0.49美元,比市场普遍预期的0.27美元高出0.22美元。该业务在本季度的收入为2.1458亿美元,而市场普遍预期为2.1483亿美元。ZimVie的负股本回报率为2.75%,负净利润率为9.96%。股票分析师平均预计,ZimVie Inc.本年度的每股收益为1.95美元。

About ZimVie

关于 ZimVie

(Get Rating)

(获取评分)

ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.

ZimVie Inc是一家医疗技术公司,开发、制造和提供一系列产品和解决方案,旨在治疗一系列脊柱疾病,并为全球的牙齿置换和修复程序提供支持。它提供牙种植系统、假体和基台产品、手术器械和套件;骨移植、屏障膜、同种异体移植和胶原蛋白伤口护理产品;口内扫描仪;以及虚拟治疗计划服务、引导手术解决方案、CAD/CAM 工作流程系统、患者特异性修复组件和口内扫描仪,以及用于各种脊柱手术、生物制剂和骨愈合技术的脊柱融合植入物和仪器。

Recommended Stories

推荐故事

  • Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
  • MarketBeat Week in Review – 1/23- 1/27
  • Why Lucid Spiked Nearly 100% In One Day
  • Ride These Railroad Stocks for Growth and Income
  • ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
  • KLA Corporation: Strength In A Troubled Semi-Market
  • 免费获取 StockNews.com 关于 ZimVie (ZIMV) 的研究报告的副本
  • MarketBeat Week 回顾 — 1/23-1/27
  • 为什么 Lucid 在一天之内飙升了近 100%
  • 利用这些铁路股票实现增长和收入
  • ASML 预计今年对芯片的需求将上涨,提振了销售前景
  • KLA 公司:在陷入困境的半市场中的实力

Want to see what other hedge funds are holding ZIMV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZimVie Inc. (NASDAQ:ZIMV – Get Rating).

想看看还有哪些对冲基金持有 ZIMV 吗? 访问Holdingschannel.com,获取ZimVie Inc.(纳斯达克股票代码:ZIMV — 获取评级)的最新13F文件和内幕交易。

Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.

接收 ZimVie Daily 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收ZimVie及相关公司的最新新闻和分析师评级的简明每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发